Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Box: Lean machine

    Asset renaissance Lean machine The assets around which Medicxi Ventures forms companies are fire-tested by a small pool of discovery scientists who help design and oversee killer experiments run by CROs. The lean …

    Published on 2/8/2016
  • Table: Asset-centric exits

    Asset renaissance Asset-centric exits The partners at Medicxi Ventures, who spun off from Index Ventures last week, have seen 10 of their asset-centric investments go public or get acquired. For companies that …

    Published on 2/8/2016
  • Asset renaissance

    How Medicxi increases Phase II successes with less capital

    Medicxi's investment model has so far had a 100% success rate in Phase II readouts while halving the capital needed to get there.

    Published on 2/8/2016
  • Results may vary

    Lessons from Amgen and Novartis U.S. risk-sharing reimbursement deals

    Early launch results for Repatha and Entresto show that U.S. payers will do risk-sharing deals, but one size does not fit all.

    Published on 2/1/2016
  • Figure: Performance progress

    Results may vary Performance progress Payers in the U.S. have disclosed at least 14 risk-sharing deals for drugs since 2009, including seven in 2015. Three of those were for lipid-lowering drug Repatha evolocumab …

    Published on 2/1/2016
  • Box: Accelerator's urban oases

    Formative years Accelerator's urban oases Accelerator Corp. is not a traditional VC, but it is forming newcos with a tight focus on two cities it sees as underserved: Seattle and New York City. The incubator seeks…

    Published on 1/25/2016
  • Figure: Early to the party

    Formative years Early to the party Shown here is the disclosed investment activity since 2010 for seven VCs where seed and series A investments make up half of the portfolio or more. The top chart displays the …

    Published on 1/25/2016
  • Formative years

    Unlocking VCs' process of biotech company formation

    VCs that create companies from scratch will continue to do so whether or not the current correction turns into something worse.

    Published on 1/25/2016
  • Pricing politics

    How value-based pricing models could calm drug pricing politics

    Both political parties have dredged up old, impractical drug pricing ideas. Better ideas are percolating below the surface.

    Published on 1/18/2016
  • Box: Laboratories of democracy

    Pricing politics Laboratories of democracy Having failed to make a dent in Washington, drug price control advocates are turning to the states, especially those that make it relatively easy to place initiatives on …

    Published on 1/18/2016
  • Box: Unrealistic prescriptions

    Pricing politics Unrealistic prescriptions Affordability of prescription drugs is the most important healthcare issue for Americans according to a national survey the Henry J. Kaiser Family Foundation released in …

    Published on 1/18/2016
  • Compounding prices

    Why ex-FDA official Joshua Sharfstein supports compounding to combat price hikes

    Joshua Sharfstein wants FDA to allow compounding of generics to combat price hikes. Critics question the approach's safety and wisdom.

    Published on 1/18/2016
  • Sowing season

    Buysiders eyeing big cap clinical milestones in 2016 to seed next growth spurt

    Buysiders are eyeing a slew of big cap clinical milestones and M&A activity to seed the next phase of growth.

    Published on 1/11/2016
  • Figure: Biotech fund flows

    Sowing season Biotech fund flows Biotech funds saw net inflows of $6 billion in 2015, despite $1.3 billion of net outflows during 4Q. The December fund flows figure below is provisional. Source: EPFR Global

    Published on 1/11/2016
  • Table: 2016 milestones

    Sowing season 2016 milestones Selected products with clinical or regulatory milestones expected in 2016. (A) Based on estimated completion date on; Source: BCIQ: BioCentury Online Intelligence…

    Published on 1/11/2016
  • Table: Approval watch

    Sowing season Approval watch Selected products up for approval in 2016. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AbbVie Inc. (NYSE:ABBV) / Enanta …

    Published on 1/11/2016
  • Table: New products to watch

    Sowing season New products to watch Selected drugs that received regulatory approval in 2015. (A) Prior approvals in parentheses; Source: BCIQ: BioCentury Online Intelligence Company Product Indication 2015 …

    Published on 1/11/2016
  • Table: Postlaunch report

    Sowing season Postlaunch report Two drugs that were first approved in 2014 — both for HCV — cracked $1 billion in 2015. Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) blew way past that mark…

    Published on 1/11/2016
  • Table: Top biotech products

    Sowing season Top biotech products At least 32 drugs developed and marketed by biotechs are expected to have more than $1 billion in 2015 sales. Antivirals from Gilead Sciences Inc. (NASDAQ:GILD) account for seven…

    Published on 1/11/2016
  • Figure: London vs. Europe

    Big band swing London vs. Europe The BioCentury Europe index gained a whopping 40% in 2015, while the BioCentury London index edged up 8%. Thirteen of 19 continental European companies in the market cap-weighted …

    Published on 1/4/2016
  • Figure: Price-to-earnings: BT vs. RX

    Big band swing Price-to-earnings: BT vs. RX The gap between big biotech and big pharma's average P/Es widened, as the former's multiple jumped 19% to 24 from 20.2 in 3Q15. Rare disease company Alexion …

    Published on 1/4/2016
  • Figure: Results by market cap

    Big band swing Results by market cap The top two market cap segments closed out the year in the black thanks to a strong 4Q showing. Companies valued at $5 billion or more were up a median of 15.7% in 4Q and 7.2% …

    Published on 1/4/2016
  • Table: 4Q approvals

    Big band swing 4Q approvals Selected 4Q approvals. Company Approval Actelion Ltd. (SIX:ATLN) / Nippon Shinyaku Co. Ltd. (Tokyo:4516) FDA approves Uptravi selexipag to treat pulmonary arterial hypertension (…

    Published on 1/4/2016
  • Table: Index performance

    Big band swing Index performance In 2015, the BioCentury 100, NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices all outperformed the general markets, as gauged by the Dow Jones Industrial …

    Published on 1/4/2016
  • Table: Restructuring watch

    Big band swing Restructuring watch At least nine companies reported workforce reductions in the fourth quarter compared to at least two in the same period last year. Table below sorted by date ascending. All cash …

    Published on 1/4/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993